Antitumor activity of a humanized, bivalent immunotoxin targeting Fn14-positive solid tumors

Keyphrases

• After Injection 50%
• AKT Pathway 50%
• Anticancer Agents 50%
• Antitumor Activity 100%
• Apoptosis 50%
• Bi-exponential 50%
• Breast 50%
• Breast Cancer Cell Lines 50%
• Breast Cancer Cells 50%
• Breast Cancer Xenograft 50%
• Cancer Xenograft Model 50%
• Cross-resistance 50%
• ErbB2 50%
• Fibroblast Growth 50%
• Gelonin 50%
• HER2+ 50%
• HER2-overexpressing Breast Cancer 50%
• Human Epidermal Growth Factor Receptor 2 (HER2) 50%
• Humanized 100%
• Immunotoxin 100%
• Inducer 50%
• Inhibition Effect 50%
• Initial Clearance 50%
• Lung 50%
• MCF-7 Cells 50%
• MDA-MB-231 50%
• MDR1 Protein 50%
• Melanoma 50%
• Multidrug Resistance Protein 1 (MDR1) 50%
• Muscle Ratio 50%
• Overexpression 50%
• Pharmacokinetic Study 50%
• Plasma Half-life 50%
• Potential Therapeutics 50%
• Protein Antibody 50%
• Protein Level 50%
• Recombinant 50%
• Recombinant Protein 50%
• Selective Agents 50%
• Solid Tumors 100%
• Synergistic Cytotoxic Effect 50%
• Therapeutic Efficacy Study 50%
• Therapeutic Index 50%
• Therapeutic Target 50%
• TNFRSF12A 50%
• Trastuzumab 50%
• Tumor 100%
• Tumor Cells 50%
• Tumor Inhibition 50%
• Tumor Subtype 100%

Immunology and Microbiology

• Akt Signaling 50%
• Antineoplastic Activity 100%
• Blood Plasma 50%
• Breast Cancer Cell Line 50%
• Cancer Cell 50%
• Cross-Resistance 50%
• Cytotoxicity 50%
• Fibroblast 50%
• Immunotoxin 100%
• Mouse 50%
• Multidrug Resistance Protein 1 50%
• Pharmacokinetics 50%
• Plasma Half Life 50%
• Protein Antibody 50%
• Trastuzumab 50%
• Tumor Cell 50%
• Tumor Necrosis Factor 50%
• Xenograft 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticarcinogen 25%
• Antitumor Activity 100%
• Breast Cancer 75%
• Cancer Inhibition 25%
• Clinical Study 25%
• Combination Therapy 25%
• Cross-Resistance 25%
• Efficacy Study 25%
• Gelonin 25%
• Immunotoxin 100%
• Melanoma 25%
• Mouse 25%
• Multidrug Resistance Protein 1 25%
• Neoplasm 100%
• Pharmacokinetics 25%
• Protein Antibody 25%
• Receptor 25%
• Recombinant Protein 25%
• Solid Malignant Neoplasm 100%
• Therapeutic Window 25%
• Trastuzumab 25%
• Tumor Necrosis Factor 25%
• Tumor Necrosis Factor Receptor Superfamily Member 12A 25%
• Tumor Protein 25%